Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001409419 | SCV001611438 | likely benign | Combined oxidative phosphorylation defect type 17 | 2020-12-03 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000866311 | SCV002575609 | uncertain significance | not provided | 2024-09-26 | criteria provided, single submitter | clinical testing | In silico analysis supports a deleterious effect on splicing; Has not been previously published as pathogenic or benign to our knowledge |
Mayo Clinic Laboratories, |
RCV000866311 | SCV005412661 | uncertain significance | not provided | 2023-10-31 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005021269 | SCV005639697 | uncertain significance | Prostate cancer, hereditary, 2; Combined oxidative phosphorylation defect type 17 | 2024-04-10 | criteria provided, single submitter | clinical testing |